Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 10, pp 1151–1153 | Cite as

Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases

  • Adam D. Elkin
  • Charlotte D. Jacobs
Original Paper



Adenoid cystic carcinoma of the salivary gland (ACC-SG) is a slow-growing tumor that is refractory to most chemotherapeutic agents. Estrogen receptor (ER) antagonists provide a novel approach for recurrent disease.


We report two cases of ACC-SC in which Tamoxifen/Toremifene were used.


Both patients obtained long-term stability of disease with no associated toxicity.


Given the relatively unsuccessful treatments for ACC-SC and the low toxicity of ER antagonists, such therapy should be considered in these patients for its potential disease-stabilizing effects.


Tamoxifen Salivary gland Adenoid cystic Estrogen receptor antagonist 


  1. Agulnik M, Siu LL (2004) An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. Curr Med Chem Anticancer Agents 4:543–551PubMedCrossRefGoogle Scholar
  2. Blackwell K, Haroon ZA, Shan S et al (2000) Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 6:4359–4364PubMedGoogle Scholar
  3. da Silva BB, da Silva RG Jr, Borges U et al (2005) Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen. J Surg Oncol 90:77–80PubMedCrossRefGoogle Scholar
  4. Dimery IW, Jones LA, Verjan RP, Raymond AK, Goepfert H, Hong WK (1987) Estrogen receptors in normal salivary gland and salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 113:1082–1085PubMedGoogle Scholar
  5. Dori S, Trougouboff P, David R, Buchner A (2000) Immunohistochemical evaluation of estrogen and progesterone receptors in adenoid cystic carcinoma of salivary gland origin. Oral Oncol 36:450–453PubMedCrossRefGoogle Scholar
  6. Garvin S, Dabrosin C (2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 63:8742–8748PubMedGoogle Scholar
  7. Hocwald E, Korkmaz H, Yoo GH et al (2001) Prognostic factors in major salivary gland cancer. Laryngoscope 111(8):1434–1439PubMedCrossRefGoogle Scholar
  8. Kang Y, Cortina R, Perry RP (1996) Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 88:279–284PubMedCrossRefGoogle Scholar
  9. Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE (2004) Adenoid cystic carcinoma of the head and neck—a 20 years experience. Int J Oral Maxillofac Surg 33(1):25–31PubMedCrossRefGoogle Scholar
  10. Locati LD, Guzzo M, Bossi P et al (2005) Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol 41:890–894PubMedCrossRefGoogle Scholar
  11. McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN, Bouchier-Hayes DJ (2001) Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 27:714–718PubMedCrossRefGoogle Scholar
  12. Nasser S, Faquin WC, Dayal Y (2003) Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors: frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 119:801–806PubMedCrossRefGoogle Scholar
  13. Shadaba A, Gaze MN, Grant HR (1997) The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 111:1186–1189PubMedCrossRefGoogle Scholar
  14. Spiro RH (1997) Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg 174:495–498PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of MedicineStanford University School of MedicineStanfordUSA

Personalised recommendations